MOBILE, Ala.–(BUSINESS WIRE)–CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced results for the fourth quarter and year ended December 31, 2023.
Fourth Quarter 2023 Financial Overview
All comparisons are to the fourth quarter ended December 31, 2022, unless otherwise noted.
Full Year 2023 Financial Overview
All comparisons are to the year ended December 31, 2022, unless otherwise noted.
“Despite the challenges we faced in 2023, we were able to finish out the year with a strong fourth quarter in terms of revenue performance, and we kicked off 2024 with the exciting news announcing our imminent rebrand to TruBridge,” said Chris Fowler, chief executive officer of CPSI. “Unifying our identity under this brand reflects our transformation as an organization that is leveraging its strengths and expertise to deliver a more cohesive and comprehensive suite of solutions to our customers.
“We believe that the investments we made to enhance our business over the past few quarters will provide us with a strong foundation from which to grow. We see a significant opportunity ahead to improve the financial health of our community hospital partners, and we are confident that our recent acquisition of Viewgol has only strengthened our position in the market. We look forward to seizing this opportunity and making further progress throughout 2024.”
First Quarter 2024 Financial Outlook1
For the first quarter 2024, the Company is providing an initial outlook of:
2024 Financial Outlook1
For the full year 2024, the Company is providing an initial outlook of:
Conference Call Information
CPSI will hold a live webcast to discuss fourth quarter and full year 2023 results today, Thursday, February 29, 2024, at 3:30 p.m. Central time/4:30 p.m. Eastern time. A 30-day online replay will be available approximately one hour following the conclusion of the live webcast. To listen to the live webcast or access the replay, visit the Company’s website, www.cpsi.com.
About CPSI
CPSI has over four decades of experience in connecting providers, patients and communities with innovative solutions that support both the clinical and financial side of healthcare delivery. We provide business, consulting, and managed information technology (IT) services, including our industry leading HFMA Peer Reviewed® suite of revenue cycle management (RCM) offerings, to help streamline day-to-day revenue functions, enhance productivity, and support the financial health of healthcare organizations. Our patient engagement solutions provide patients and providers with the critical information and tools they need to share existing clinical data and analytics that support value-based care, improve outcomes, and increase patient satisfaction. We support efficient patient care across an expansive base of community hospitals with electronic health record (EHR) product offerings that successfully integrate data between care settings. We make healthcare accessible through data-driven insights that support informed decisions and deliver workflow efficiencies, while keeping patients at the center of care. We are a healthcare solutions company. We clear the way for care. For more information, please visit www.cpsi.com.
|
1 |
Excluding revenues, the Company does not provide guidance on a GAAP basis as certain items that impact Adjusted EBITDA or non-GAAP net income such as severance and other nonrecurring charges, which may be significant, are outside the Company’s control and/or cannot be reasonably predicted. Please see the “Explanation of Non-GAAP Financial Measures” at the end of this press release for detailed information on calculating non-GAAP measures. For a reconciliation of other non-GAAP financial measures, see the non-GAAP financial reconciliation tables in this release. |
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “predicts,” “intends,” “plans,” “potential,” “may,” “continue,” “should,” “will” and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to the Company’s future financial and operational results are forward-looking statements. We caution investors that any such forward‑looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forward‑looking statements. Such factors may include: a public health crisis, such as the COVID-19 pandemic, and related economic disruptions; saturation of our target market and hospital consolidations; unfavorable economic or market conditions that may cause a decline in spending for information technology and services; significant legislative and regulatory uncertainty in the healthcare industry; exposure to liability for failure to comply with regulatory requirements; transition to a subscription-based recurring revenue model and modernization of our technology; competition with companies that have greater financial, technical and marketing resources than we have; potential future acquisitions that may be expensive, time consuming, and subject to other inherent risks; our ability to attract and retain qualified client service and support personnel; disruption from periodic restructuring of our sales force; potential inability to properly manage growth in new markets we may enter; exposure to numerous and often conflicting laws, regulations, policies, standards or other requirements through our international business activities; potential litigation against us; our reliance on an international workforce which exposes us to various business disruptions; potential failure to develop new products or enhance current products that keep pace with market demands; failure of our products to function properly resulting in claims for medical and other losses; breaches of security and viruses in our systems resulting in customer claims against us and harm to our reputation; failure to maintain customer satisfaction through new product releases free of undetected errors or problems; failure to convince customers to migrate to current or future releases of our products; failure to maintain our margins and service rates; increase in the percentage of total revenues represented by service revenues, which have lower gross margins; exposure to liability in the event we provide inaccurate claims data to payors; exposure to liability claims arising out of the licensing of our software and provision of services; dependence on licenses of rights, products and services from third parties; misappropriation of our intellectual property rights and potential intellectual property claims and litigation against us; interruptions in our power supply and/or telecommunications capabilities, including those caused by natural disaster; potential inability to secure additional financing on favorable terms to meet our future capital needs; our substantial indebtedness, and our ability to incur additional indebtedness in the future; pressures on cash flow to service our outstanding debt; restrictive terms of our credit agreement on our current and future operations; changes in and interpretations of financial accounting matters that govern the measurement of our performance; significant charges to earnings if our goodwill or intangible assets become impaired; fluctuations in quarterly financial performance due to, among other factors, timing of customer installations; volatility in our stock price; failure to maintain effective internal control over financial reporting; lack of employment or non-competition agreement with most of our key personnel; inherent limitations in our internal control over financial reporting; vulnerability to significant damage from natural disasters; market risks related to interest rate changes; potential material adverse effects due to macroeconomic conditions, including bank failures or changes in related regulation; and other risk factors described from time to time in our public releases and reports filed with the Securities and Exchange Commission, including, but not limited to, our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. We also caution investors that the forward-looking information described herein represents our outlook only as of this date, and we undertake no obligation to update or revise any forward-looking statements to reflect events or developments after the date of this press release.
|
Computer Programs and Systems, Inc. |
|||||||||||||||
|
Condensed Consolidated Statements of Income |
|||||||||||||||
|
(In ‘000s, except per share data) |
|||||||||||||||
|
(Unaudited) |
|||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
| Revenues | |||||||||||||||
| RCM |
$ |
50,956 |
|
$ |
45,670 |
|
$ |
193,929 |
|
$ |
179,870 |
|
|||
| EHR |
|
33,412 |
|
|
35,968 |
|
|
138,063 |
|
|
139,823 |
|
|||
| Patient engagement |
|
1,500 |
|
|
1,586 |
|
|
7,443 |
|
|
6,955 |
|
|||
| Total revenues |
|
85,868 |
|
|
83,224 |
|
|
339,435 |
|
|
326,648 |
|
|||
| Expenses | |||||||||||||||
| Costs of revenue (exclusive of amortization and depreciation) | |||||||||||||||
| RCM |
|
28,731 |
|
|
25,956 |
|
|
110,192 |
|
|
97,024 |
|
|||
| EHR |
|
14,153 |
|
|
17,497 |
|
|
62,048 |
|
|
65,661 |
|
|||
| Patient engagement |
|
810 |
|
|
1,061 |
|
|
3,628 |
|
|
3,856 |
|
|||
| Total costs of revenue (exclusive of amortization and depreciation) |
|
43,694 |
|
|
44,514 |
|
|
175,868 |
|
|
166,541 |
|
|||
| Product development |
|
10,347 |
|
|
9,001 |
|
|
37,246 |
|
|
31,898 |
|
|||
| Sales and marketing |
|
6,143 |
|
|
4,553 |
|
|
28,049 |
|
|
27,131 |
|
|||
| General and administrative |
|
21,682 |
|
|
14,650 |
|
|
76,153 |
|
|
54,965 |
|
|||
| Amortization |
|
6,974 |
|
|
5,687 |
|
|
24,522 |
|
|
20,887 |
|
|||
| Depreciation |
|
554 |
|
|
553 |
|
|
1,946 |
|
|
2,443 |
|
|||
| Impairment of goodwill |
|
35,913 |
|
|
– |
|
|
35,913 |
|
|
– |
|
|||
| Impairment of trademark intangibles |
|
2,342 |
|
|
– |
|
|
2,342 |
|
|
– |
|
|||
| Total expenses |
|
127,649 |
|
|
78,958 |
|
|
382,039 |
|
|
303,865 |
|
|||
| Operating income (loss) |
|
(41,781 |
) |
|
4,266 |
|
|
(42,604 |
) |
|
22,783 |
|
|||
| Other income (expense): | |||||||||||||||
| Other income |
|
176 |
|
|
264 |
|
|
745 |
|
|
1,178 |
|
|||
| Gain (loss) on contingent consideration |
|
– |
|
|
(427 |
) |
|
– |
|
|
565 |
|
|||
| Loss on extinguishment of debt |
|
– |
|
|
– |
|
|
– |
|
|
(125 |
) |
|||
| Interest expense |
|
(4,116 |
) |
|
(2,276 |
) |
|
(12,521 |
) |
|
(6,320 |
) |
|||
| Total other income (expense) |
|
(3,940 |
) |
|
(2,439 |
) |
|
(11,776 |
) |
|
(4,702 |
) |
|||
| Income (loss) before taxes |
|
(45,721 |
) |
|
1,827 |
|
|
(54,380 |
) |
|
18,081 |
|
|||
| Provision (benefit) for income taxes |
|
(3,247 |
) |
|
(690 |
) |
|
(8,591 |
) |
|
2,214 |
|
|||
| Net income (loss) (1) |
$ |
(42,474 |
) |
$ |
2,517 |
|
$ |
(45,789 |
) |
$ |
15,867 |
|
|||
| Net income (loss) per common share—basic |
$ |
(2.92 |
) |
$ |
0.17 |
|
$ |
(3.15 |
) |
$ |
1.08 |
|
|||
| Net income (loss) per common share—diluted |
$ |
(2.92 |
) |
$ |
0.17 |
|
$ |
(3.15 |
) |
$ |
1.08 |
|
|||
| Weighted average shares outstanding used in per common share computations: | |||||||||||||||
| Basic |
|
14,205 |
|
|
14,210 |
|
|
14,187 |
|
|
14,356 |
|
|||
| Diluted |
|
14,205 |
|
|
14,210 |
|
|
14,187 |
|
|
14,356 |
|
|||
| (1) In connection with the Company’s disposition of AHT in January 2024 and other factors, management is finalizing certain line items in the financial statements included herein, primarily related to the amount of goodwill impairment. Any change to the amount of goodwill impairment set forth in this earnings release (and the corresponding impact on related line items) is not expected to be material. The final amount of goodwill impairment and the amounts of impacted line items for fiscal year 2023 will be reflected in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Any change to the amounts for the fourth quarter of 2023 will be provided on the Investor Relations portion of the Company’s website. | |||||||||||||||
|
Computer Programs and Systems, Inc. |
|||||||
|
Condensed Consolidated Balance Sheets |
|||||||
|
(In ‘000s, except per share data) |
|||||||
|
|
|
|
|
||||
|
|
December 31, 2023 (unaudited) |
|
December 31, 2022 |
||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents |
$ |
3,848 |
|
$ |
6,951 |
|
|
| Accounts receivable, net of allowance for expected credit losses of $3,631 and $2,854, respectively |
|
59,723 |
|
|
51,311 |
|
|
| Financing receivables, current portion (net of allowance for expected credit losses of $319 and $223, respectively) |
|
3,997 |
|
|
4,474 |
|
|
| Inventories |
|
475 |
|
|
784 |
|
|
| Prepaid income taxes |
|
1,628 |
|
|
701 |
|
|
| Prepaid expenses and other |
|
15,807 |
|
|
10,338 |
|
|
| Assets of held for sale disposal group |
|
25,754 |
|
|
– |
|
|
| Total current assets |
|
111,232 |
|
|
74,559 |
|
|
| Property & equipment, net |
|
8,974 |
|
|
9,884 |
|
|
| Software development costs, net |
|
39,139 |
|
|
27,257 |
|
|
| Operating lease assets |
|
5,192 |
|
|
7,567 |
|
|
| Financing receivables, net of current portion (net of allowance for expected credit losses of $97 and $326, respectively) |
|
1,226 |
|
|
3,312 |
|
|
| Other assets, net of current portion |
|
7,314 |
|
|
8,131 |
|
|
| Intangible assets, net |
|
89,213 |
|
|
102,000 |
|
|
| Goodwill |
|
171,909 |
|
|
198,253 |
|
|
| Total assets |
$ |
434,199 |
|
$ |
430,963 |
|
|
| Liabilities & Stockholders’ Equity | |||||||
| Current liabilities | |||||||
| Accounts payable |
$ |
10,133 |
|
$ |
7,035 |
|
|
| Current portion of long-term debt |
|
3,141 |
|
|
3,141 |
|
|
| Deferred revenue |
|
8,677 |
|
|
11,590 |
|
|
| Accrued vacation |
|
5,410 |
|
|
6,214 |
|
|
| Liabilities of held for sale disposal group |
|
754 |
|
|
– |
|
|
| Other accrued liabilities |
|
19,892 |
|
|
16,475 |
|
|
| Total current liabilities |
|
48,007 |
|
|
44,455 |
|
|
| Long-term debt, net of current portion |
|
195,270 |
|
|
136,388 |
|
|
| Operating lease liabilities, net of current portion |
|
3,074 |
|
|
5,651 |
|
|
| Deferred tax liabilities |
|
1,230 |
|
|
12,758 |
|
|
| Total liabilities |
|
247,581 |
|
|
199,252 |
|
|
| Stockholders’ Equity | |||||||
| Common stock, $0.001 par value; 30,000 shares authorized; 15,121 and 14,913 shares issued, respectively |
|
15 |
|
|
15 |
|
|
| Treasury stock, 572 and 483 shares, respectively |
|
(17,075 |
) |
|
(14,500 |
) |
|
| Additional paid-in capital |
|
195,546 |
|
|
192,275 |
|
|
| Retained earnings |
|
8,132 |
|
|
53,921 |
|
|
| Total stockholders’ equity |
|
186,618 |
|
|
231,711 |
|
|
| Total liabilities and stockholders’ equity |
$ |
434,199 |
|
$ |
430,963 |
|
|
|
Computer Programs and Systems, Inc. |
|||||||
|
Condensed Consolidated Statements of Cash Flows |
|||||||
|
(In ‘000s) |
|||||||
|
(Unaudited) |
|||||||
|
|
|
|
|
||||
|
|
Twelve Months Ended December 31, |
||||||
|
|
|
2023 |
|
|
|
2022 |
|
| Operating activities: | |||||||
| Net income (loss) |
$ |
(45,789 |
) |
$ |
15,867 |
|
|
| Adjustments to net income: | |||||||
| Provision for credit losses |
|
1,920 |
|
|
992 |
|
|
| Deferred taxes |
|
(11,305 |
) |
|
(6,688 |
) |
|
| Stock-based compensation |
|
3,271 |
|
|
5,173 |
|
|
| Depreciation |
|
1,946 |
|
|
2,443 |
|
|
| Loss on extinguishment of debt |
|
– |
|
|
125 |
|
|
| Amortization of acquisition-related intangibles |
|
16,426 |
|
|
17,403 |
|
|
| Amortization of software development costs |
|
8,096 |
|
|
3,484 |
|
|
| Amortization of deferred finance costs |
|
359 |
|
|
332 |
|
|
| Impairment of goodwill |
|
35,913 |
|
|
– |
|
|
| Impairment of trademark intangibles |
|
2,342 |
|
|
– |
|
|
| Gain on contingent consideration |
|
– |
|
|
(565 |
) |
|
| Non-cash operating lease costs |
|
1,602 |
|
|
– |
|
|
| Loss on disposal of PP&E |
|
117 |
|
|
– |
|
|
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable |
|
(11,319 |
) |
|
(12,428 |
) |
|
| Financing receivables |
|
2,659 |
|
|
6,144 |
|
|
| Inventories |
|
309 |
|
|
71 |
|
|
| Prepaid expenses and other |
|
(4,554 |
) |
|
(2,930 |
) |
|
| Accounts payable |
|
3,075 |
|
|
(1,429 |
) |
|
| Deferred revenue |
|
(2,913 |
) |
|
61 |
|
|
| Operating lease liabilities |
|
(2,063 |
) |
|
– |
|
|
| Other liabilities |
|
1,894 |
|
|
422 |
|
|
| Prepaid income taxes |
|
(927 |
) |
|
3,898 |
|
|
| Net cash provided by operating activities |
|
1,059 |
|
|
32,375 |
|
|
| Investing activities: | |||||||
| Purchase of business, net of cash acquired |
|
(36,705 |
) |
|
(43,364 |
) |
|
| Investment in software development |
|
(23,059 |
) |
|
(19,097 |
) |
|
| Purchases of property and equipment |
|
(346 |
) |
|
(270 |
) |
|
| Net cash used in investing activities |
|
(60,110 |
) |
|
(62,731 |
) |
|
| Financing activities: | |||||||
| Treasury stock purchases |
|
(2,575 |
) |
|
(11,924 |
) |
|
| Proceeds from long-term debt |
|
– |
|
|
575 |
|
|
| Payments of long-term debt principal |
|
(3,500 |
) |
|
(3,563 |
) |
|
| Proceeds from revolving line of credit |
|
67,023 |
|
|
48,000 |
|
|
| Payments of revolving line of credit |
|
(5,000 |
) |
|
(5,300 |
) |
|
| Payments of contingent consideration |
|
– |
|
|
(1,935 |
) |
|
| Proceeds from exercise of stock options |
|
– |
|
|
23 |
|
|
| Net cash provided by (used in) financing activities |
|
55,948 |
|
|
25,876 |
|
|
| Decrease in cash and cash equivalents |
|
(3,103 |
) |
|
(4,480 |
) |
|
| Cash and cash equivalents, beginning of period |
|
6,951 |
|
|
11,431 |
|
|
| Cash and cash equivalents, end of period |
$ |
3,848 |
|
$ |
6,951 |
|
|
|
Computer Programs and Systems, Inc. |
|||||||||||
|
Consolidated Bookings |
|||||||||||
|
(In ‘000s) |
|||||||||||
|
|
|
|
|
|
|
|
|||||
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
|||||||||
| In ‘000s |
2023 |
|
2022 |
|
2023 |
|
2022 |
||||
| RCM(1) |
$ |
14,158 |
$ |
13,373 |
$ |
48,986 |
$ |
48,065 |
|||
| EHR(2) |
|
10,888 |
|
10,678 |
|
33,143 |
|
38,152 |
|||
| Patient engagement(1) |
|
969 |
|
620 |
|
2,973 |
|
3,188 |
|||
| Total |
$ |
26,015 |
$ |
24,671 |
$ |
85,102 |
$ |
89,405 |
|||
|
(1) Generally calculated as the total contract price (for non-recurring, project-related amounts) and annualized contract value (for recurring amounts). |
|||||||||||
|
(2) Generally calculated as the total contract price (for system sales) and annualized contract value (for support) for perpetual license system sales and total contract price for SaaS sales. |
|||||||||||
Contacts
Tracey Schroeder
Chief Marketing Officer
Tracey.schroeder@cpsi.com
(251) 639-8100
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (Euronext…
BEIJING--(BUSINESS WIRE)--Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered…
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF…
SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO),…
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology…
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX,…
